Pharmaceuticals | JNJ Innovation

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we envision a world without disease. To achieve this, we strive to couple our strong internal capabilities with the most compelling external science to transform how diseases are thought of being treated, cured, prevented and intercepted in the future.

Focus Areas

Our Pharmaceuticals business is divided into six core areas, Cardiovascular & Metabolism; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. We seek innovation across all of these areas where there is significant unmet patient need.

We are also pioneering Data Science and digital healthcare and reimagining how we Discover, Develop & Supply transformational medicines to patients around the world.

CLICK a circle below to see the diseases we are targeting.

Cardivascular and Thrombosis,
Retinal Diseases,
Metabolism/NASH,
Renal Disease

CARDIOVASCULAR, METABOLISM AND RETINA

CARDIOVASCULAR, METABOLISM AND RETINA
Gastroenterology,
Rheumatology & Maternal-fetal immunology,
Immuno Dermatology,
Autoantibody pathway

Immunology

Immunology
Viral Hepatitis & Adjacent Liver Diseases,
Prevention & Treatment of Viral & Bacterial Respiratory Infections,
Adjuvants, Novel Viral Vectors & Vaccine Technologies

Infectious
Diseases and Vaccines

Infectious Diseases and Vaccines
Mood Disorders,
Neurodegenerative Disorders including Multiple Sclerosis,
Schizophrenia

Neuroscience

Neuroscience
Prostate Cancer,
Hematologic Malignancies,
Solid Tumor Targeted Therapy,
Immuno-Oncology

Oncology

Oncology
Pulmonary Hypertension (all groups), Adjacent rare cardiopulmonary diseases

Pulmonary Hypertension

Pulmonary Hypertension
• Small molecule & protein therapeutics
• mRNA & siRNA therapeutics
• Cell & gene therapeutics
• Data & analytics

Discovery, Product Development & Supply

Discovery, Product Development & Supply
• Drug Discovery: AI & Machine Learning (ML) to drive:
- High-value biological insights & targets
- Reduced cycle time & improved NME quality
• Drug Development: AI & ML to drive:
- Improved clinical trial design, including early detection, better endpoints & patient stratification
- Accelerated clinical trial operations
- Enhanced Diversity & Inclusion
• Real-World Evidence (RWE) & external control arms to augment regulatory submissions & internal decisions

• Digital health & treatments, Software as a Medical Device & decentralized trials to enhance care

Data Science

Data Science

Collaboration Partners

Johnson & Johnson Innovation is comprised of a family of complementary teams that bring meaningful solutions and flexible approaches to support collaboration. From incubation facilities to early-stage investing – from venture funding to acquisition, our teams offer partners a full range of capabilities.

Text left

JLABS
If you are seeking incubation space for your early-stage company, or seeking to expand your start-up through an exchange of ideas and collaboration, make the connection with our incubation teams.